RSS
Links
-
Recent Posts
- (no title)
- Flu Challenge Studies at NIH
- Politics and Plagues
- OPERATION WHITECOAT
- You may hold the cure for the next epidemic
- National Security Implications of CRISPR-CAS9
- If Not Me, Then Who?
- JUMP START: ACCELERATING GOVERNMENT RESPONSE TO A NATIONAL BIOLOGICAL CRISIS
- The Reemergent 1977 H1N1 Strain and the Gain-of-Function Debate
- Ebola 2014: Pandemic Preparedness Lessons Learned
- Mitigating the Risks of Synthetic Biology
- Tracking Down Smallpox Before It Kills Anew
- Penn and Teller on the Anti-Vaccine Idiots
- Interview about WMD Center’s Report Card on Bio-Response
- John Snow Society Pump Handle Lecture Series 2013
Monthly Archives: October 2012
Michael G. Kurilla Describes Key Contributions of NIAID to US Biosecurity: Part I
Michael G. Kurilla, MD, PhD Director Office of BioDefense Research Affairs, National Institute of Allergy and Infectious Diseases (NIAID) Description Dr. Kurilla describes the key contributions of the National Institute of Allergy and Infectious Diseases to US biosecurity, including early … Continue reading
Posted in Uncategorized
Leave a comment
Robert Kadlec Discusses 3 Key Improvements to US Biodefense Policy
Robert Kadlec, MD Former Special Assistant to the President for Biodefense Policy Description Dr. Kadlec discusses 3 key improvements to US biodefense policy that he believes are achievable within 5 years. Dr. Kadlec has served in both the executive and … Continue reading
Posted in Uncategorized
Leave a comment
Interview with Luciana Borio
Luciana Borio, MD
Assistant Commissioner for Counterterrorism Policy and Director, Office of Counterterrorism and Emerging Threats in the Office of the Chief Scientist, US Food and Drug Administration
Description
In this interview, Dr. Borio outlines the evolving role that the Food Drug Administration (FDA) has assumed in the development of medical countermeasures. Under Dr. Borio’s leadership, the FDA has established the Medical Countermeasure Initiative (MCMi), which is an effort to hasten the development of these products, and to improve their odds of achieving FDA approval. The MCMi has made investments in improving the regulatory science that will be necessary for government’s ability to evaluate a new generation of medical products. Here, Dr. Borio discusses some of the successes that the FDA has achieved in this arena, such as the ability to evaluate and approve multiplex diagnostic assays, as well as the challenges that remain.
Video produced by the Center for Biosecurity of UPMC
Posted in Uncategorized
Leave a comment
Interview with Phyllis Arthur
Phyllis Arthur
Senior Director, Vaccines, Immunotherapeutics and Diagnostics Policy, Biotechnology Industry Organization
Description
The timely availability of medical countermeasures—drugs, vaccines and other medical resources needed for a robust response—is a key component of US biosecurity. Ms. Arthur discusses the role of public-private partnerships in drug and vaccine development and production and broadly outlines the roles that Congress, the Administration, and the private sector play regarding US biodefense policy.
As a senior leader at the Biotechnology Industry Organization (BIO), Ms. Arthur has a unique and critical role at the interface between the resources and requirements of the US government and the research, development, manufacturing, and production capabilities of private industry.
Video produced by the Center for Biosecurity of UPMC
Posted in Uncategorized
Leave a comment
http://www.upmc-biosecurity.org/website/resources/multimedia/2012_behind_the_scenes/01_arthur.html
From the Center for Biosecurity of UPMC
Posted in Uncategorized
Leave a comment